Phaseline

Targets › BCAT1

BCAT1 (Branched-chain-amino-acid aminotransferase, cytosolic): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. (UniProt, P54687)

Open in Phaseline: the race on BCAT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Alnylam PharmaceuticalsALN-BCAT
BCAT1 inhibitor
BCAT1Phase 1Advanced Hepatocellular CarcinomaSep 2027

Conditions

Advanced Hepatocellular Carcinoma (1)

Modalities

mixed (1)

Companies

Alnylam Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.